Stock PTX PRESCIENT THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 01:36:52 2024-05-03 am EDT 		5-day change 1st Jan Change
0.046 AUD -4.17% Intraday chart for Prescient Therapeutics Limited -11.54% -25.81%
Mar. 25 Transcript : Prescient Therapeutics Limited - Special Call
Feb. 23 Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 23.31 14.98 21.29 157.1 101.4 65.23
Enterprise Value (EV) 1 17.86 5.322 14.07 141.1 89.14 43.31
P/E ratio -9.02 x -2.45 x -6.41 x -36 x -19.6 x -8.41 x
Yield - - - - - -
Capitalization / Revenue 21.9 x 9.09 x 19.7 x 132 x 53.7 x 26.9 x
EV / Revenue 16.8 x 3.23 x 13 x 119 x 47.2 x 17.8 x
EV / EBITDA -7.03 x -1.37 x -4.12 x -33.3 x -17.1 x -5.81 x
EV / FCF -13.9 x -1.86 x -11.2 x -55.9 x -37.1 x -11.3 x
FCF Yield -7.22% -53.8% -8.94% -1.79% -2.69% -8.86%
Price to Book 2.47 x 1.05 x 1.9 x 7.69 x 6.05 x 2.5 x
Nbr of stocks (in thousands) 211,865 394,261 394,261 641,053 654,323 805,270
Reference price 2 0.1100 0.0380 0.0540 0.2450 0.1550 0.0810
Announcement Date 8/31/18 8/25/19 8/25/20 8/30/21 8/22/22 8/24/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 1.065 1.648 1.079 1.185 1.889 2.428
EBITDA 1 -2.54 -3.896 -3.414 -4.241 -5.209 -7.456
EBIT 1 -2.541 -3.897 -3.415 -4.242 -5.21 -7.458
Operating Margin -238.62% -236.52% -316.39% -357.8% -275.76% -307.15%
Earnings before Tax (EBT) 1 -2.574 -3.797 -3.321 -4.149 -5.117 -7.005
Net income 1 -2.574 -3.797 -3.321 -4.149 -5.117 -7.005
Net margin -241.68% -230.45% -307.71% -349.97% -270.85% -288.47%
EPS 2 -0.0122 -0.0155 -0.008423 -0.006800 -0.007899 -0.009627
Free Cash Flow 1 -1.289 -2.864 -1.257 -2.523 -2.401 -3.838
FCF margin -121.06% -173.79% -116.47% -212.86% -127.11% -158.07%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/31/18 8/25/19 8/25/20 8/30/21 8/22/22 8/24/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 5.45 9.66 7.22 16 12.3 21.9
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.29 -2.86 -1.26 -2.52 -2.4 -3.84
ROE (net income / shareholders' equity) -24.3% -32% -26% -26.2% -27.5% -32.7%
ROA (Net income/ Total Assets) -14.3% -19.5% -15.8% -16% -16.9% -20.4%
Assets 1 18 19.48 21.07 25.85 30.32 34.36
Book Value Per Share 2 0.0400 0.0400 0.0300 0.0300 0.0300 0.0300
Cash Flow per Share 2 0.0300 0.0200 0.0200 0.0300 0.0200 0.0100
Capex 1 0 - - 0 0 -
Capex / Sales 0.14% - - 0.2% 0.23% -
Announcement Date 8/31/18 8/25/19 8/25/20 8/30/21 8/22/22 8/24/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PRESCIENT THERAPEUTICS LIMITED Stock Prescient Therapeutics Limited
-25.81% 25.29M
MODERNA, INC. Stock Moderna, Inc.
+24.38% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.38% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.95% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.68% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.83% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.80% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.08% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.37% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PTX Stock
  4. Financials Prescient Therapeutics Limited